{"id":8822,"date":"2025-10-01T12:35:38","date_gmt":"2025-10-01T09:35:38","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8822"},"modified":"2025-10-01T12:35:39","modified_gmt":"2025-10-01T09:35:39","slug":"mavacamten-evidence-in-obstructive-vs-nonobstructive-hcm","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/mavacamten-evidence-in-obstructive-vs-nonobstructive-hcm\/","title":{"rendered":"Mavacamten-Evidence in Obstructive vs. Nonobstructive HCM"},"content":{"rendered":"<div>Mavacamten-Evidence in Obstructive vs. Nonobstructive HCM<\/div>\n<div><\/div>\n<div>Source (ESC 2025, Madrid): NEJM 2025 \u2013 ODYSSEY-HCM. JACC 2025 \u2013 COLLIGO-HCM<\/div>\n<div><\/div>\n<div>Keynotes:<\/div>\n<div><span> 1. Proven efficacy in obstructive HCM:<\/span><\/div>\n<div><span> \u2022 The EXPLORER-HCM trial (NEJM 2020) demonstrated that mavacamten significantly improved exercise capacity, symptoms, and quality of life, while reducing LV outflow tract gradients in patients with symptomatic obstructive HCM.<\/span><\/div>\n<div><span> \u2022 These results led to FDA approval in 2022 (Camzyos, Bristol Myers Squibb) as the first pharmacologic therapy for symptomatic obstructive HCM. (NEJM 2020)<\/span><\/div>\n<div><span> 2. Lack of benefit in nonobstructive HCM:<\/span><\/div>\n<div><span> \u2022 In the ODYSSEY-HCM Phase III trial (NEJM, Sept 2025), mavacamten did not outperform placebo in improving peak oxygen uptake or KCCQ-CSS symptom scores over 48 weeks in patients with symptomatic nonobstructive HCM.<\/span><\/div>\n<div><span> \u2022 Participants had resting LVOT gradients &lt; 30 mm Hg (&lt; 50 mm Hg with provocation), NYHA class II\u2013III, and LVEF \u2265 60%.<\/span><\/div>\n<div><span> \u2022 Authors suggested that in nonobstructive disease, symptoms may result more from diastolic dysfunction, ischemia, ventricular stiffness, and altered energetics, conditions less responsive to myosin inhibition.<\/span><\/div>\n<div><span> \u2022 Commentary highlighted that this negative outcome confirms that nonobstructive HCM is not simply a mirror image of obstructive HCM, stressing the need for novel therapeutic approaches.\u00a0<\/span><\/div>\n<div><\/div>\n<div><a href=\"http:\/\/www.jacc.org\/doi\/10.1016\/S0735-1097%2825%2901741-3\">http:\/\/www.jacc.org\/doi\/10.1016\/S0735-1097%2825%2901741-3\u00a0<\/a><\/div>\n<div><\/div>\n<div>NEJM 2025 \u2013 ODYSSEY-HCM (negative trial results) \u2014 <a href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2505927.\">http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2505927.<\/a><\/div>\n<div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Mavacamten-Evidence in Obstructive vs. Nonobstructive HCM Source (ESC 2025, Madrid): NEJM 2025 \u2013 ODYSSEY-HCM. JACC 2025 \u2013 COLLIGO-HCM Keynotes: 1. Proven efficacy in obstructive HCM: \u2022 The EXPLORER-HCM trial (NEJM 2020) demonstrated that mavacamten significantly improved exercise capacity, symptoms, and quality of life, while reducing LV outflow tract gradients in patients with symptomatic obstructive HCM. [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-8822","post","type-post","status-publish","format-standard","hentry"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8822","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8822"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8822\/revisions"}],"predecessor-version":[{"id":8823,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8822\/revisions\/8823"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8822"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8822"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8822"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}